Navigation Links
Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
Date:6/12/2012

AUSTIN, Texas, June 12, 2012 /PRNewswire/ -- Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions, today announced positive top-line data from its AeroVanc Phase I clinical study in patients with cystic fibrosis (CF). 

AeroVanc, a dry powder formulation of vancomycin, is the first inhaled antibiotic being developed for the treatment of respiratory methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with CF.  The dose-escalating Phase I clinical study examined the tolerability, safety and pharmacokinetics of AeroVanc in non-MRSA infected CF patients. AeroVanc was well tolerated and safe and produced high concentrations of vancomycin in the sputum.  In line with the pharmacokinetic results in healthy volunteers, the clearance of vancomycin from the lungs was slow, indicating a favorable profile for once- or twice-daily dosing.

"Persistent MRSA lung infection in CF patients has been associated with faster decline of lung function and significantly shortened survival. Whereas inhaled antibiotics have become a cornerstone of treatment of Pseudomonas infections in CF, there are currently no approved inhaled drugs available to treat MRSA lung infection," said Elliott C Dasenbrook, Associate Director of the Adult Cystic Fibrosis Program at Case Western University.  "Pulmonary delivery of vancomycin is a very promising treatment concept to ensure high drug concentrations at the site of infection, while minimizing systemic toxicity and treatment burden."

"In this trial we have demonstrated sputum concentrations of vancomycin known to effectively kill MRSA, and we therefore have high confidence in being able to suppress or even eradicate the infection with AeroVanc in our Phase IIa study in MRSA-infected patients," said Robert Neville, Chief Executive Officer, Savara. 

Savara also recently announced a successful Series B fundraising of $8.6 million.  Proceeds from the financing will support AeroVanc's advancement through the Phase IIa clinical study, scheduled to start early next year.

About AeroVanc

AeroVanc (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration.  Vancomycin administered by IV is the antibiotic of choice for the treatment of MRSA-related bronchopneumonia, however, IV administration, poor penetration into the lungs and systemic toxicities limit its use in a chronic setting.  AeroVanc is the first inhaled antibiotic being developed for the treatment of MRSA infection in cystic fibrosis patients.  By delivering vancomycin directly to the site of infection, AeroVanc is expected to improve clinical efficacy and reduce adverse effects due to systemic drug exposure.

AeroVanc has demonstrated positive safety and tolerability results in a Phase I clinical study conducted in healthy subjects and patients with cystic fibrosis, with a pharmacokinetic profile that supports its potential as a once- or twice-daily treatment for pulmonary MRSA infections.

About Cystic Fibrosis and MRSA

Cystic fibrosis is a genetic disease characterized by the prevalence of thick, sticky mucus produced in the lung, frequent lung infections and a resultant decline in pulmonary function.  As the disease progresses, patients' lungs are typically colonized with bacteria that are difficult to eradicate. Such infections are typically treated with inhaled antibiotics, which have become one of the cornerstones in the treatment of cystic fibrosis over the last decade. In recent years, infection and colonization by MRSA has become increasingly common, with a prevalence of almost 30 percent of all cystic fibrosis patients in the United States.  Persistent MRSA infection has been found to cause a faster decline in lung function and to be associated with a significantly shortened life expectancy.  Currently there is no approved inhaled treatment for MRSA infection in cystic fibrosis patients. 

About Savara Pharmaceuticals

Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions.  The company's lead product, AeroVanc (vancomycin hydrochloride inhalation powder), is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals To Host Investor Day
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
4. Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. SOCMAs Bulk Pharmaceuticals Task Force Welcomes House Passage of FDA Reform Act
7. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
8. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
9. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
10. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
(Date:1/19/2017)... 19, 2017 Conference Call and Webcast to Follow ... announced it will release results for the fourth quarter of 2016 ... ... conference call at 4:30 PM ET on Wednesday, February 15, 2017, ... 2016 financial results and other corporate activities. To participate in the ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you ... from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty ... ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower ...
(Date:1/21/2017)... ... 21, 2017 , ... In the United States, 20 million women and 10 ... they often feel shame for having struggled with an eating disorder as well as ... “Rising Strong in Life After an Eating Disorder” -- to be featured at this ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... in homes across the world. Yisrayl says this generation is a time like no other ... turn to the Bible. , Yisrayl says he does not want to sound like an ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
Breaking Medicine News(10 mins):